Arecor, 네덜란드에서 Ogluo® 출시 발표
Arecor Therapeutics plc
("Arecor", "회사" 또는 "그룹")
ARECOR ANNOUNCES LAUNCH OF OGLUO® IN THE NETHERLANDS
- Launch builds on continued pan-European commercial roll-out following earlier launches in Denmark, Norway, Austria, Germany and the UK
Cambridge, UK, 29 February 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, notes the announcement today from subsidiary company, Tetris Pharma Ltd, that Ogluo® (glucagon prefilled autoinjector pen) has been launched in the Netherlands as a treatment for severe hypoglycaemia in adults, adolescents, and children aged two years and over living with diabetes mellitus.
Ogluo® has been launched in the Netherlands by Goodlife, under the previously announced, existing commercialisation agreement between Tetris Pharma Ltd and Goodlife, which has established Goodlife as the sole partner for the import, marketing and distribution of the product in the BeNeLux region.
See full Tetris Pharma announcement below:
Ogluo® launches in the Netherlands
Availability of glucagon prefilled autoinjector pen in first BeNeLux country, in partnership with Goodlife, further expands reach of Ogluo® across Europe
Continued momentum in pan European roll-out following earlier launches in Denmark, Norway, Austria, Germany and the UK
29 February 2024 - Tetris Pharma Ltd ("Tetris Pharma" or "the Company"), a subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC), today announces the launch of Ogluo® (glucagon prefilled autoinjector pen) in the Netherlands as a treatment for severe hypoglycaemia in adults, adolescents, and children aged two years and over living with diabetes mellitus.
The launch is part of an existing exclusive commercialisation agreement between Tetris Pharma Ltd and Goodlife, announced in September 2023, which established Goodlife as the sole partner for the import, marketing and distribution of the product in the BeNeLux region.
Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon in an auto-injector for patients within the licenced indication living with diabetes suffering from severe hypoglycaemia. Today's launch builds on the continued roll-out of Ogluo® across key European markets, including, Denmark, Norway, Austria, Germany and the UK, as part of Tetris Pharma's pan-European commercialisation programme.
Dr. Helen Parris, Senior Vice President, Commercial and General Manager of Tetris Pharma, commented: "The launch of Ogluo® in the Netherlands presents a significant milestone for Tetris Pharma, strengthening the commercial reach and pan-European presence of this important product and giving patients living with diabetes who may experience severe hypoglycaemia, a treatment option to tackle those events. Goodlife's leading know-how and expertise of regional market dynamics make them an ideal partner to support with the roll-out of Ogluo® in the BeNeLux region. We look forward to continuing to expand our reach within Europe to bring this treatment option to people living with diabetes."
편집자 주
Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage specialty pharmaceutical company with expertise in registering, marketing, sales and the distribution of speciality hospital products across the UK and Europe. Our experienced team has a proven history of building and growing sales. Having secured distribution rights for already licensed products across Europe, we have a portfolio of niche injectable products including Ogluo®, a ready-to-use glucagon for emergency use to treat hypoglycaemia. We collaborate with partners to provide patients with effective treatments and quality healthcare by ensuring we deliver accountability, partnership and performance. For further information, please visit www.tetrispharma.com.
Goodlife is a privately owned pharmaceutical company with a focus on The Netherlands, Belgium and Luxembourg. Goodlife believes that every patient deserves excellent care that matches their individual needs, even if those needs deviate from the norm. With this in mind, we strive for customization every day, by providing unique medicines, medical devices, dietary supplements and supportive tools for individual patients in the BeNeLux. For more information, please visit www.goodlifepharma.com.
-ENDS-
자세한 내용은 문의하시기 바랍니다 :
Arecor Therapeutics plc | www.arecor.com |
CEO 사라 하웰 박사 | 전화 : + 44 (0) 1223 426060 이메일 : [이메일 보호] |
Susan Lowther, 최고 재무 책임자 | 전화 : + 44 (0) 1223 426060 이메일 : [이메일 보호] |
| |
Panmure Gordon (영국) 제한 (노마드와 Broker) | |
프레디 크로슬리, 엠마 얼(기업 금융) Rupert Dearden(기업 중개) | 전화 : + 44 (0) 20 7886 2500
|
WG 파트너스 LLP (Financial Advisor) | |
Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang | 전화 : + 44 (0) 203 705 9321 |
ICR 콘실리움 | |
크리스 가드너, 데이비드 데일리, 린지 네빌 | 전화 : + 44 (0) 20 3709 5700 이메일 : [이메일 보호] |
|
편집자 주
아레코 소개
Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat?, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat? platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.